Jupiter Topco LLC Acquires New Holdings in Septerna, Inc. $SEPN

Jupiter Topco LLC bought a new stake in Septerna, Inc. (NASDAQ:SEPN) during the 2nd quarter, Holdings Channel.com reports. The fund bought 1,307,500 shares of the company’s stock, valued at approximately $43,723,000.

A number of other large investors have also added to or reduced their stakes in SEPN. Group One Trading LLC boosted its holdings in shares of Septerna by 111.8% in the 4th quarter. Group One Trading LLC now owns 944 shares of the company’s stock valued at $26,000 after buying an additional 8,955 shares in the last quarter. Global Retirement Partners LLC bought a new position in shares of Septerna during the 4th quarter worth approximately $35,000. Russell Investments Group Ltd. purchased a new stake in Septerna during the third quarter valued at approximately $36,000. Caitong International Asset Management Co. Ltd purchased a new stake in Septerna during the fourth quarter valued at approximately $53,000. Finally, Balyasny Asset Management L.P. acquired a new stake in Septerna in the fourth quarter valued at approximately $100,000.

Insiders Place Their Bets

In other Septerna news, COO Elizabeth Bhatt sold 25,000 shares of Septerna stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $44.00, for a total transaction of $1,100,000.00. Following the completion of the sale, the chief operating officer directly owned 174,209 shares in the company, valued at approximately $7,665,196. The trade was a 12.55% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, SVP Daniel D. Long sold 15,000 shares of the stock in a transaction on Monday, June 22nd. The stock was sold at an average price of $35.51, for a total transaction of $532,650.00. Following the completion of the sale, the senior vice president owned 96,412 shares in the company, valued at $3,423,590.12. The trade was a 13.46% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 61,030 shares of company stock valued at $2,329,666. 5.80% of the stock is owned by insiders.

Analysts Set New Price Targets

SEPN has been the topic of several analyst reports. JPMorgan Chase & Co. lifted their price target on shares of Septerna from $38.00 to $48.00 and gave the stock an “overweight” rating in a report on Wednesday, August 19th. Wells Fargo & Company raised their price objective on Septerna from $48.00 to $50.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 12th. JonesTrading boosted their target price on Septerna from $43.00 to $62.00 and gave the stock a “buy” rating in a research note on Thursday, August 13th. Stifel Nicolaus set a $49.00 target price on Septerna in a research report on Tuesday, August 11th. Finally, HC Wainwright increased their price target on Septerna from $40.00 to $60.00 and gave the company a “buy” rating in a research note on Wednesday, August 12th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $52.44.

Septerna Trading Up 0.5%

NASDAQ:SEPN opened at $40.47 on Friday. Septerna, Inc. has a twelve month low of $11.70 and a twelve month high of $51.10. The company has a market cap of $1.89 billion, a PE ratio of -74.94 and a beta of 2.29. The company’s 50 day moving average is $37.24 and its two-hundred day moving average is $30.75.

Septerna (NASDAQ:SEPN) last posted its quarterly earnings results on Monday, August 10th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.14. Septerna had a negative net margin of 24.51% and a negative return on equity of 9.57%. The business had revenue of $26.75 million during the quarter, compared to analysts’ expectations of $19.22 million. As a group, analysts expect that Septerna, Inc. will post -1.41 EPS for the current fiscal year.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.